MDB Capital Holdings (MDBH) Q3 2026 earnings review
MDB's eXoZymes stake shrank, and its spin-off deals are late
MDB Capital, which launches and backs young technology companies, lost value on its biggest holding while its planned exits slipped. It cut the value of its stake in eXoZymes, a listed enzyme-chemistry company, by $9.9 million. The quarter's net loss reached $16 million, against $5 million a year ago. Chief executive Christopher Marlett said costs will drop once outside investors fund two of its units.
| Fee income, first nine months | $4.2M +96% from a year ago |
|---|---|
| Cut to the value of the eXoZymes stake | $9.9M stake now valued at $22.9M |
| Cash | $8.3M $13.2M at the end of 2025 |
| Outlook for spin-offs and listings | Pushed back PatentVest independence now 2027; Paulex listing first half of 2027 |
โ๏ธ Verdict: ๐ด Bearish
The story got worse because every step meant to cut costs and return value moved later. No Public Ventures deal arrived, and PatentVest and Paulex Bio now point to 2027. One positive: nine-month fees nearly doubled, so income covered more of the costs.
The question now is whether MDB signs outside funding for its brokerage and patent firm before cash runs low. If the deals close, costs fall and MDB needs no new shares; if not, it may sell stock Marlett pledged to avoid. The annual results will tell.
๐ Bull Case
Deal Fees Nearly Doubled in Nine Months
MDB earns fees when Public Ventures, its brokerage arm, arranges share sales for young companies. Those fees reached $4.2 million in nine months, up 96%. Chief executive Christopher Marlett said they eased the cash drain this year.
- Third-quarter fees: $333,000, against nothing a year ago
- Fees from eXoZymes, a company MDB part-owns: $892,000 of the total
- Fees and other income: about 9% of third-quarter costs, by our math
But the gain leans on a few deals. Most fees arrived in the first half, and one came from eXoZymes, where MDB holds 42%. That is why the third quarter brought in so little.
What to watch: full-year fee income in the annual report. MDB planned two more deals for the second half, and the total will show how much of its costs fees can cover.
eXoZymes Picked Curia for Large-Scale Manufacturing
eXoZymes is a listed company, 42% owned by MDB, that makes compounds with enzymes outside living cells. MDB said eXoZymes chose Curia, a contract manufacturer, as its first commercial-scale partner "to support technology transfer and scale-up of NCT", its lead supplement ingredient.
The step matters because earlier companies in this field could not make their products in volume. Chief executive Christopher Marlett said eXoZymes now makes NCT for under $1,000 a kilo, against an early estimate of $3,500.
But eXoZymes has signed no partner to sell NCT yet, so the compound earns no revenue. Marlett said eXoZymes needs such partners because it discovers and makes compounds but does not market them.
What to watch: a signed sales partner for NCT, which eXoZymes would announce. A deal would give MDB's largest holding its first route to revenue.
๐ป Bear Case
Every Promised Exit Moved Later
MDB's plan rests on four holdings reaching a turning point, then passing their value to investors. Two are its own units: Public Ventures, a brokerage that settles its own customers' trades, and PatentVest, its patent law firm. Last quarter chief executive Christopher Marlett aimed to wrap up a Public Ventures deal within three months.
No deal arrived. MDB said it is still talking with partners about steps including "a potential launch independent of MDB", and Marlett said "we hope to conclude a transaction". Every other date moved as well.
- Public Ventures: in talks, no signed partner
- PatentVest: independence now planned for 2027, not 2026
- Paulex Bio trial: first dosing in December, not mid-2026
- Paulex Bio listing: first half of 2027, not late 2026
This matters because each delay keeps the units' costs on MDB's books and pushes back any payout. Paulex Bio, a private diabetes-drug developer, faces a pass-or-fail test too: its pill must first prove safe in people.
What to watch: a signed Public Ventures agreement and Paulex's first dosing in December. A signed deal would be the first exit in the plan to actually close.
MDB Cut the Value of Its Biggest Holding
eXoZymes, the listed enzyme-chemistry company in which MDB owns 42%, is MDB's largest asset. Its quoted market value has stayed below MDB's cost since May, so MDB cut the stake's value by $9.9 million this quarter, the filing shows.
- Stake value: $22.9 million, against $37.5 million at the end of 2025
- Share of MDB's total assets: 61%
- Losses when eXoZymes sold new shares: $1.4 million this year
This matters because MDB plans to hand eXoZymes shares to its own investors, chief executive Christopher Marlett said. But eXoZymes is raising money again, president George Brandon said, so a new share sale could shrink MDB's slice.
The filing also contradicts itself. Its text puts the charge at $9.23 million, while its table shows $9.86 million. MDB has not explained the gap.
What to watch: the stake's value in the annual report, after eXoZymes' new share sale. Another cut would leave MDB's payout plan resting on a smaller asset.
Costs Rose 13% While MDB Called Them Flat
MDB's release called operating expenses "flat compared to both the prior year and the prior quarter". Over nine months that is close, because costs fell 3%. In the third quarter alone, costs climbed 13% from a year ago, the filing's figures show.
- Professional fees: up 37%, for outside patent consultants
- Information technology: up 32%, for the brokerage's new platform
- Other overhead: up 37%, mainly a share grant for services
- Staff pay: up 6%, which MDB put down to "raises and distribution of stock"
The gap matters because cash pays these bills. Cash fell to $8.3 million from $9.6 million in June, and part of it must stay inside Public Ventures to meet broker capital rules.
Share awards cost investors too. Class A shares outstanding grew 8.5% in a year, even as chief executive Christopher Marlett said "the last thing I want to see is dilution". MDB also paid $1.44 million in nine months to a Nicaraguan services firm its principal members control.
What to watch: quarterly operating costs in the annual report. A clear drop would show that the cuts Marlett promised have started.
Small-Company Markets Still Block New Launches
MDB makes money by taking young technology companies public, earning fees and warrants, which are rights to buy shares later. Chief executive Christopher Marlett said MDB launched no new companies "purely because of the backdrop of the current market".
He had aimed for two to four launches a year, a pace that "has just not been feasible in this market environment". Because small stocks fell, the market also cut what MDB already holds.
- Paper losses on held stocks and warrants: $5.95 million this year
- Brokerage's holdings of stocks and warrants: $2.5 million, against $7.2 million in December
What to watch: the number of deals MDB closes in the fourth quarter, reported with the annual results. Two closed deals would show the market has started to reopen for its clients.
๐ Other Themes
MDB Plans to Hand Holdings to Investors in 2027
MDB set itself up as a limited liability company so it could pass holdings straight to its investors. Chief executive Christopher Marlett said "we expect to have distributions in 2027 of those assets to the shareholders", with eXoZymes the easiest because it already trades. MDB said its board "is reviewing potential structures for sharing any value realized with shareholders".
๐ฒ Other KPIs
Equity per share, meaning MDB's recorded assets minus its debts for each share, fell to $3.41 from $5.88 a year ago, by our math. It has dropped for three straight quarters, and fastest in the third, because net losses outran the equity added through share awards.
Net capital at Public Ventures, the cushion regulators require a broker to hold, stayed at $7.85 million, about the same as a year ago. The broker promised a settlement body to keep at least $5.25 million. So only about $2.6 million could move up to MDB, by our math.
Working capital, meaning current assets minus bills due within a year, fell 37% to $9.9 million from a year earlier. MDB said it spent the money to fund operations, and it raised no outside cash in the nine months.
๐ฎ Guidance
Cut. MDB now plans to make PatentVest, its patent law firm, an independent company in 2027, after it raises outside money. Last quarter the plan called for standalone funding during 2026. Until that money arrives, MDB keeps paying the firm's costs, so the delay also postpones the savings.
Cut. Marlett said Paulex Bio, the private diabetes-drug developer MDB backs, would like to go public in the first half of 2027. Last quarter's plan targeted late 2026. Paulex has filed its registration papers confidentially, and a listing would make its shares easy for MDB to hand to investors.
Cut. Paulex now expects to give the first trial patients its pill in December. Marlett said the team had aimed for September and runs "about 2 months behind". The trial first tests safety, then whether the pill regrows the cells that make insulin. Last quarter's plan put those first results in the first half of 2027.
Held, but without a figure. MDB's presentation says operating "costs fall significantly" once outside investors fund Public Ventures and PatentVest. Last quarter's plan named $5โ6 million a year. Third-quarter costs ran at $5.65 million. Reaching that target means cutting roughly three-quarters of spending, by our math.
โ Key Questions
When will MDB name a partner for Public Ventures?
Marlett aimed last quarter to wrap up a deal within three months. Until a partner takes over, MDB pays the costs of the brokerage and patent unit, which ran $1.8 million in the quarter.
Did the two planned second-half deals close?
MDB planned two deals for the second half, and third-quarter fees stayed small. The answer decides how much of the costs fees can cover this year.
What will MDB spend each quarter after the spin-offs?
The presentation dropped last quarter's $5โ6 million yearly target. Investors need a figure to judge how long the remaining cash lasts without new shares.
Why does the filing show two write-down figures?
The eXoZymes note cites $9.23 million in its text and $9.86 million in its table. It also puts MDB's share of the eXoZymes loss above what the income statement implies.
How much cash can the parent company actually spend?
Public Ventures must hold capital for regulators, and a $2 million credit line rests on a matching cash deposit. MDB does not split its cash between the parent and the brokerage.
